. $6.7bn for a IBD drug is kind of the going rate, depending on stage of development. Roche recently bought a TLA2 for a similar amount, and Takeda bought a TYK2i for $4bn despite no data in IBD at all (just PsO or AD, I forgot which) - just for its potential in GI indications. It’s the whole ‘pipeline in a product’ concept: the drugs th…
. $6.7bn for a IBD drug is kind of the going rate, depending on stage of development. Roche recently bought a TLA2 for a similar amount, and Takeda bought a TYK2i for $4bn despite no data in IBD at all (just PsO or AD, I forgot which) - just for its potential in GI indications. It’s the whole ‘pipeline in a product’ concept: the drugs that have sold best are in autoimmune conditions (think Dupixent, Humira, etc) and they are what helps when you’re facing a patent cliff. Which is a problem Pfizer is facing along with much of the rest of the industry.
The only thing it’s better to have is a GLP1 in obesity. But we will see what happens there. I suspect a huge number of lawsuits in future.
Oh and why GSK stayed out of the COVID debacle is a long story. They were offered the chance to get in on the AZ vaccine by Oxford , but either didn’t move fast enough or someone sensible in the organisation hesitated, as the AAV approach was known to have clotting issues (GSK had recently stopped development of one in RSV for safety reasons). AZ likely didn’t have that insight and went for it.
GSK didn’t think mRNA would work (didn’t think the fda and other regulators would be as complicit as they were, more accurately) and decided to work on an adjuvanted antigen based approach with sanofi, which reached the market far too late to get much use and do much harm.
. $6.7bn for a IBD drug is kind of the going rate, depending on stage of development. Roche recently bought a TLA2 for a similar amount, and Takeda bought a TYK2i for $4bn despite no data in IBD at all (just PsO or AD, I forgot which) - just for its potential in GI indications. It’s the whole ‘pipeline in a product’ concept: the drugs that have sold best are in autoimmune conditions (think Dupixent, Humira, etc) and they are what helps when you’re facing a patent cliff. Which is a problem Pfizer is facing along with much of the rest of the industry.
The only thing it’s better to have is a GLP1 in obesity. But we will see what happens there. I suspect a huge number of lawsuits in future.
Oh and why GSK stayed out of the COVID debacle is a long story. They were offered the chance to get in on the AZ vaccine by Oxford , but either didn’t move fast enough or someone sensible in the organisation hesitated, as the AAV approach was known to have clotting issues (GSK had recently stopped development of one in RSV for safety reasons). AZ likely didn’t have that insight and went for it.
GSK didn’t think mRNA would work (didn’t think the fda and other regulators would be as complicit as they were, more accurately) and decided to work on an adjuvanted antigen based approach with sanofi, which reached the market far too late to get much use and do much harm.